<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00987662</url>
  </required_header>
  <id_info>
    <org_study_id>AUTH170909</org_study_id>
    <nct_id>NCT00987662</nct_id>
  </id_info>
  <brief_title>Irbesartan Versus Amlodipine: The OBI Study</brief_title>
  <acronym>OBI</acronym>
  <official_title>Double Blind Study of Irbesartan vs. Amlodipine in Obese Hypertensive Subjects- The OBI Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aristotle University Of Thessaloniki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aristotle University Of Thessaloniki</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective:

        1. To study the effectiveness of irbesartan 300mg and amlodipine 10 mg in 24h ambulatory
           blood pressure values in obese subjects

        2. To study the drug specific effect in arterial stiffness

        3. To study possible drug mechanisms in obesity (reduction of central adiposity and
           changing the ratio of leptin to adiponectin)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Objectives

        1. Primary:

             -  Reduction of 24h BP in obese hypertensives

             -  Reduction in arterial stiffness

        2. Secondary

             -  Drug specific effect on new onset of diabetes

             -  Drug specific effect on reduction in central fat deposition and the leptin to
                adiponectin ratio

      Study design

      Study drugs: Irbesartan 300mg vs. amlodipine 10mg

      Tx duration and follow-up: 12 months

      Collected data:

        -  24h SBP and DBP in time 0, 1, 12.

        -  Pulse wave velocity in time 0,1,12.

        -  Central obesity (total, visceral, abdominal fat) in time 0,1,12.

        -  Leptin/adiponectin in time 0,1,12.

        -  BMI, waist/hip ratio in time 0,1, 12.

        -  Glu, HbA1c, insulin in time 0, 1,12.

        -  K, Na, Cr, BUN, Chol, Tg, HDL, LDL,ALT, AST in time 0, 1,12. Number of patients: The
           reduction in mean SBP expected to be 15 mmHg. Previous studies from our group reported
           an 14mmHg SD for mean SBP. The sample size required at the two sided 5% significance
           level and 80% power is 40 patients (Lehr's formula)

      Number of centers: 1
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    no funding
  </why_stopped>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">January 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of 24h BP and arterial stiffness in obese hypertensives</measure>
    <time_frame>12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>New onset of diabetes</measure>
    <time_frame>12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug specific effect on reduction in central fat deposition and the leptin to adiponectin ratio</measure>
    <time_frame>12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Obesity</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Irbesartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with irbesartan 300mg for 4 weeks. IF ABP&gt;135/85 mmHg add HCZ 12.5 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amplodipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with amlodipine 10 mg for 4 weeks. If BP&gt;135/85 mmHg add hydrochlorothiazide 12.5 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irbesartan</intervention_name>
    <description>Treatment with irbesartan 300mg for 4 weeks. IF ABP&gt;135/85 mmHg add hydrochlorothiazide 12.5 mg.</description>
    <arm_group_label>Irbesartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>Treatment with amlodipine 10 mg for 4 weeks. If ABP&gt;135/85 mmHg add hydrochlorothiazide 12.5 mg</description>
    <arm_group_label>Amplodipine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age between 18 and 60 years.

          2. All patients are going to give their informed consent to participate in the study.

          3. Stage I hypertension.

          4. BMI &gt; 30.

        Exclusion Criteria:

          1. Known oversensitiveness,

          2. Chronic renal disease (GFR &lt; 50 ml/min) or ESRD,

          3. Heart or respiratory failure, OR

          4. Recent MI, shock, liver deficiency (ALT or AST &gt; 3 times normal and pregnancy or
             lactation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vasilios Kotsis, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>AUTH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hypertension-24h ABPM Center Papageorgiou Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2009</study_first_submitted>
  <study_first_submitted_qc>September 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2009</study_first_posted>
  <last_update_submitted>February 10, 2014</last_update_submitted>
  <last_update_submitted_qc>February 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2014</last_update_posted>
  <responsible_party>
    <name_title>Kotsis Vasilios/Prof</name_title>
    <organization>Papageorgiou hospital hypertension/24h ABPM center</organization>
  </responsible_party>
  <keyword>irbesartan</keyword>
  <keyword>amlodipine</keyword>
  <keyword>obesity</keyword>
  <keyword>ambulatory blood pressure monitoring</keyword>
  <keyword>new onset diabetes</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irbesartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

